Supplementary Table S2 from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S2 shows time course of peripheral neuropathy development during treatment with Teliso-V monotherapy Q2W and Q3W cohorts and peripheral neuropathy events leading to Teliso-V dose interruption/reduction
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4404025516